Background: Recombinant human bone morphogenetic proteins (rhBMPs) have been characterized especially chondrogenic and osteogenic activity both in vitro and in vivo studies. However, delivery of more than one growth factor by sustained release carrier to orthopedic site has yet been questionable in terms of efficacy and synergism. Objective: Evaluate osteoinductivity and synergistic effect of rhBMP-2 and -7 using absorbable collagen sponge (ACS) carrier system in vivo. Methods: cDNA of BMP-2 and -7 active domains were cloned and expressed in Escherichia coli BL21 Star
Bone morphogenetic proteins (BMPs), belonging to the protein super-family of transforming growth factor-β (TGF-β), remain being hot spots for tissue engineering research. BMPs play multifunctional roles in the regulation of growth, differentiation, and apoptosis of various cell types. They exhibit important functions especially during embryonic development and tissue morphogenesis, including chondrogenesis and osteogenesis [1] [2] [3] . Many studies concerning osteoinductive property of over 20 BMPs characterized were conducted, but only a few members have been verified to have potential osteoinductive property. The BMP-2 and BMP-7, also known as osteogenic protein-1 (OP-1), have been extensively demonstrated in the osteogenic activity both in vitro and in vivo bioassay [4, 5] . The benefit of BMPs in induction of mesenchymal stem cells to undergo osteoblastic differentiation have led to the application of recombinant BMPs for promoting bone healing and treatment of bone defects. BMP-2 and BMP-7 have been approved by the FDA as therapeutic protein targets for clinical applications, i.e. long bone fractures and spinal fusion, due to their potent osteoinductive activity.
To date, recombinant biotechnology has been applied for simple and high-yielded production of the attractive proteins including BMPs. Both BMP-2 and -7 have been commercially cloned and expressed to meet a large therapeutic demand. Traditionally, clinical achievement in the use of rhBMPs also requires the biomaterial which functions as a sustained-release and biocompatible matrix carrier. This requires the capability of carrier to either hold or protect the growth factor from degradation at the site of implantation. Nowadays, absorbable collagen sponge (ACS) has been considered as the qualified candidate for both experimental and clinical studies [6, 7] . Many studies have been reported on evaluating the efficacy of BMPs in conjunction with ACS for local repair of bone defects and de novo ectopic bone formation. However, the formulation using the ACS combined with both BMP-2 and - 7 has not yet been elucidated.
In this study, we postulated that the combination of rhBMP-2 and -7 might synergistically induce ectopic bone formation when combined to ACS. To prove this hypothesis, we examined the osteogenic induction of ACS combined with either rhBMPs, compared to only ACS and ACS with either rhBMP alone in the in vivo rat subcutaneous implant model.
Materials and methods

Animals
Forty male Wistar rats weighing 200-250 g were purchased from National Laboratory Animal Center, Mahidol University, Nakhon Pathom, Thailand. Rats were individually housed in stainless steel cages under diurnal lighting cycles at 23±2 °C and fed standard rat laboratory food and water ad libitum. The animal experiments were conducted according to the guidelines of the Institutional Animal Care and Use Committee (IACUC) and approved by the Ethics Committee of the Faculty of Medicine, Chulalongkorn University.
Construction of pRSETc/BMP-2 and pRSETc/ BMP-7 expression vectors
An osteosarcoma-derived cell line, Saos-2 (American Type Culture Collection, Manassas, USA), was selected as a cell source for BMP expression. Total RNA was extracted from osteosarcoma cells using the RNeasy Mini Kit (Qiagen, Valencia, USA) according to the protocols provided by the manufacturer. The coding region of both mature BMP-2 and -7 were amplified by RT-PCR using total osteosarcoma RNA as a template. The following primer pairs: bmp2F (5' GGATCCAAGCCAAACA CAAACAG 3') and bmp2R (5' AAGCTTAGCGA CACCCACAACCCTC 3') for BMP-2; bmp7F (5' CTGCAGCTGTCCACGGGGAGCAAACAG 3') and bmp7R (5' AAGCTTAGTGGCAGCCACAGG CCCG 3') for BMP-7, were used for cDNA amplification. The underlined nucleotides for cloning purposes were represented as BamHI and HindIII restriction sites for BMP-2 and PstI and HindIII restriction sites for BMP-7 in the forward and reverse primers respectively. The amplicon corresponding mature BMP-2 domain was initially cloned into pGEM T-easy vector (Promega, Madison, USA). After positive clone selection, DNA fragments encoding mature domain of BMP-2 and -7 were digested and sub-cloned in frame downstream of N-terminal 6x histidine (His) tag in a pRSETc expression vector (Invitrogen, Carlsbad, USA), resulting in the construct pRSETc/BMP-2 and pRSETc/BMP-7 respectively. Construction of expression plasmids as described above was done in Escherichia coli strain DH5α and verified for correct insertion by automated DNA sequencing analyses.
Expression of rhBMP-2, -7 proteins
The recombinant plasmid pRSETc/BMP-2 and pRSETc/BMP-7 were individually transformed into E. coli BL21 Star TM (DE3) (Invitrogen, Carlsbad, USA) for expression experiments. A freshly transformed colony of E.coli was inoculated into Luria Bertani (LB) broth containing 100 μg/mL ampicillin and incubated overnight at 37°C with 200 rpm. The overnight starter was diluted 1:100 in LB-ampicillin and incubated at 37°C until an OD 600 value reached approximately 0.4-0.6. Then, the culture was induced for protein expression by adding isopropyl β-Dthiogalactopyranoside (IPTG) to a final concentration of 0.5 mM and allowed to grow at 18°C with 180 rpm for an additional 18 hours. The bacterial cells were harvested by centrifugation at 4,000xg for 10 minutes at 4°C. The pellet was washed twice with phosphate buffered saline (PBS) and kept frozen at -80°C until use.
Purification of rhBMP-2, -7 inclusion bodies
The frozen pellet was resuspended in PBS supplemented with lysozyme to a final concentration of 0.5 mg/mL and incubated on ice for 30 minutes prior to sonication four times with a burst duration of 15 seconds each. Briefly, the pellet fraction containing rhBMP inclusion bodies was washed in wash buffer, pH 8.0 (50 mM NaH 2 PO 4 , 300 mM NaCl, 0.5% Triton X-100), centrifuged (12,000xg at 4°C for 15 minutes), and resuspended in buffer B, pH 8.0 (50 mM NaH 2 PO 4 , 300 mM NaCl, 1 mM phenylmethylsulfonyl fluoride (PMSF) and 8 M urea) at 4°C for 30 minutes with gentle agitation. After centrifugation to remove insoluble material (12,000xg at 4°C for 20 minutes), the supernatant was collected as urea-solubilized fraction.
The proteins of interest were purified under denaturing condition using Ni 2+ -nitrilotriacetic acid (Ni-NTA) spin kit (Qiagen, Valencia, USA). Briefly, the solubilized fraction was applied onto a column preequilibrated with buffer B. The column was washed thrice with buffer C, pH 8.0 (50 mM NaH 2 PO 4 , 300 mM NaCl, 250 mM imidazole and 8 M urea). Finally, the bound His-tagged rhBMP was eluted with buffer E, pH 8.0 (50 mM NaH 2 PO 4 , 300 mM NaCl, 250 mM imidazole and 8 M urea). Refolding using the SnakeSkin® dialysis tubing (Pierce, Rockford, USA) was performed in a stepwise manner as follows: 100 volumes of the dialysate 1 (50 mM NaH 2 PO 4 , pH 8.0, 100 mM NaCl, 0.1 mM dithiotreitol (DTT) and 5 M urea), 100 volumes of the dialysate 2 (50 mM NaH 2 PO 4 , pH 8.0, 125 mM NaCl and 2.5 M urea), and 100 volumes of the dialysate 3 (50 mM NaH 2 PO 4 , pH 8.0 and 150 mM NaCl), for three hours, respectively. The dialysis process was all carried out at 4°C. Then, the refolded proteins were applied to HiTrap TM heparin-sepharose columns (GE Healthcare, Uppsala, Sweden) as previously described [11] for dimer purification. Aliquots of the refolded dimer were used for protein quantitation by the bicinchoninic acid (BCA) protein assay (Pierce, Rockford, USA) using bovine serum albumin as a standard.
Absorbable collagen sponges preparation
Absorbable collagen sponge was prepared from pepsin-treated type I collagen. Briefly, pepsin-treated type I collagen was dissolved in 0.05 mM acetic acid at final concentration of 0.8% (w/v). Then, 1 mL of collagen solution was poured into wells and frozen at -20°C for 24 hours. The frozen collagen was lyophilized and then incubated at 37°C and 80°C under vacuum condition for at least three hours and 24 hours, respectively. The sponge was cut into small pieces with 6 mm diameter and 2 mm thickness using biopsy punch and finally UV-irradiated for two hours.
In vivo rhBMPs/ACS implantation
The rhBMP-2 and -7 solution were individually loaded onto collagen sponges with 5 μg of total protein amount for rhBMP-2/ACS and rhBMP-7/ACS and 2.5 μg of each for rhBMP-2 and -7/ACS. The pieces of collagen sponges were then incubated for two hours at 37°C prior to the operation. The rats were anesthesized, shaved and disinfected with povidone iodine at dorsal surface. The incisions were vertically performed at the paravertebral back skin to implant the sponges at the subcutaneous tissues. Two and eight weeks postoperatively, the implants were removed from the sacrifices, fixed in 10% neutral buffered formalin for 24 hours and embedded in paraffin prior to sectioning. The 5 μm thick sections were stained by conventional hematoxylin-eosin (H&E) method and verified by light microscopy.
Results
Expression of rhBMP-2 and -7
Complete cDNA fragments encoding mature domain of BMP-2 and -7 were successfully amplified via RT-PCR using RNA template from osteosarcoma cell. After verifying inframe insertion by DNA sequencing, rhBMP cDNAs were subcloned from pGEM T-easy vector into pRSETc expression vector and induced by 0.5 mM IPTG to express heterologous protein in E. coli BL21 Star TM (DE3) under T7 RNA polymerase/promoter system. The insoluble pellets were obtained after sonication and solubilized in denaturing condition. The solubilized fraction was then loaded into Ni-NTA spin column for first-step His-tag purification. The purified sample was stepwise dialyzed for excessive urea removal and in vitro refolding. Finally, monomers and polymers were excluded from active dimers by heparin affinity chromatography with NaCl gradient elution.
In vivo rat subcutaneous model
The numbers of Wistar rats giving positive result of new bone formation are shown in Table 1 .
At two weeks, a large number of inflammatory cells, especially both polymorphonuclear and mononuclear cells, were markedly infiltrated in ACS control (Fig. 1) , particularly in the periphery of the implant but new blood vessel invasion was limited.
Unsurprisingly, ectopic bone formation was evident in ACS implants soaked with rhBMP(s). For rhBMP-2/ACS (Fig. 2) and rhBMP-7/ACS (Fig. 3) , newly synthesized collagen was extensively well-organized into osteoid matrix islets with osteoblast lining at the periphery of the implant without evidence of significant adverse reaction. Considering rhBMP-7/ ACS, angiogenesis was not pronounced, compared to rhBMP-2/ACS experiments. In case of rhBMP-2 and -7/ACS (Fig. 4) , osteoid matrix, observed at the edge of implants, was more extensively well-organized into trabeculae-like structure with osteoblast lining than other experimental groups. Some osteoblasts were embedded in small lacunae of osteoid matrix. In addition, multinucleated giant cell could be found along the rim indicating the evidence of remodeling. Neovascularization was also extensively pronounced like the rhBMP-2/ACS group, without significant inflammation. At eight weeks, neither residual collagen sponge nor the newly formed bone was observed due to possible degradation.
Discussion
BMP-2 and -7 are the most potent osteoinductive cytokines belonging to TGF-β super family. Extensive studies have reported that these BMPs signaling play the key role in regulation of cartilage and bone formation [1, 2] . Another striking feature was that the solved crystal structure of BMP-2 at 2.7 angstrom resolution has been shown to be very similar to that of BMP-7. Therefore, this structural similarity reflected their resembled biological role [8, 9] .
At present, both BMP-2 and -7 are widely applied in both in vitro and in vivo researches as well as clinical therapeutic purposes. Therefore, recombinant DNA and protein purification technology were required for producing these therapeutic cytokines. The expression of heterologous forms of the early BMPs was accomplished using mammalian cell lines, most particularly Chinese hamster ovary cells [4, 10] . However, several methods had been successfully developed for producing fully functional BMPs in E. coli expression system [11] [12] [13] .
To produce active rhBMPs, transformants harboring pRSETc/BMP-2 and -7 were induced by IPTG to express the protein of interest. Expectedly, highly-yielded insoluble BMPs were obtained. We have attempted to adjust growth temperature, IPTG concentration, and medium component, but the solubility was not yet improved (data not shown). A possible explanation for these findings was that our eukaryotic proteins were expressed in prokaryotic system lacking post-translational modifications such as glycosylation and disulfide bond formation, essential for fully functional and correctly folded dimeric BMPs. Although some studies had attempts to insert periplasmic localizing sequence at N-terminal for enhancing disulfide bond formation and proper conformation at periplasmic space, those expressed proteins were yet in form of inclusion bodies [13] . However, our heterologous dimeric BMPs after two -step purification had retained biological activities when co-implanted with absorbable collagen sponge in rat subcutaneous tissue.
We could successfully demonstrate the effect of rhBMP-2 and -7 in combination with collagen sponge carrier to in vivo ectopic bone formation in the rat subcutaneous model. The rat subcutaneous bone formation assay has been the standard method used to evaluate the osteoinductive potential of BMPs. Implantation of purified recombinant BMP with collagen matrix in subcutaneous sites in rats induces a sequence of cellular events that eventually results in the formation of new bone. Although this subcutaneous model would remarkably show the new bone formation in amount and maturation aspect less than the calvarial defect model, this ectopic model could presumably exclude the osteogenic effects of several growth factors from orthopedic site.
Bone has very high potential to self-repair and regenerate a new bone identical to the native tissue. Thus, to evaluate the potency of rhBMPs when combined with ACS, the subcutaneous model was conducted to enable the exclusion of the intrinsic effect from surrounding native bone and clarify the hypothesis. Nevertheless, the growth factor concentration for optimal osteoinduction had been yet a controversial issue. Visser et al. [14] demonstrated the achievement of new bone formation at rhBMP-2 concentration of 0.5 g. Kubler et al. [15] , in contrast, claimed that higher dose (40 g) was required for more effective osteoinduction in ectopic sites. In the present study, 5 μg of total purified protein, determined as the optimal dose of rhBMP(s) in each group, yielded a satisfactory result. Obviously, newly ectopic bone in subcutaneous tissue could be observed after two weeks post-implantation in all rhBMP-treated groups. Compared to the effects induced by only BMP-2 or -7 alone, well-organized osteoid trabeculae and new blood vessel invasion were significantly exhibited in response to implantation with both rhBMPs. To a point of interest, BMP-2 (or -4) binds preferentially to BMPRIA/ALK-3 and BMPRIB/ALK-6 whereas BMP-7 (or -6) had higher affinity to ALK-2 [16, 17] . Under these conditions, it was worth noting that significant ectopic bone formation observed with the combination of neovascularization could be due to the synergistic or combined effect of these two potent osteoinductive cytokines.
The mechanism underlying the synergistic or combined effect of these two BMPs remains to be elucidated. Despite the different receptors required for individual BMP signaling, overlapping expression and co-localization during mouse embryogenesis had been reported [18, 19] . Israel et al. [20] established that heterodimeric BMP-2 and -7 was more potent than BMP-2 in both in vitro and in vivo assays. Intriguingly, it was possible that the more potent in vivo osteoinductive event in case of BMP-2 and -7 combination may be accompanied with the activation of downstream signaling cascades via two different subtypes of type I BMP receptors, ALK3/6 and ALK2. In parallel with our speculation, Aoki et al. [21] concluded that transcriptional activity determined by luciferase assay was significantly up-regulated in C2C12 cells co-transfected with ALK-2 and ALK-3 DNAs in synergistic fashion. In addition, in vitro alkaline phosphatase activity of C2C12 cells stimulated by two different BMPs isoforms, BMP-4 and -6, was synergistically increased, in comparison to induction with either BMP alone. Their findings might reflect the synergistic effect of BMP-2 and -7 in cooperation determining osteoblastic differentiation in the present study.
